Side-by-side · Research reference
TB-500vsThymalin
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 2Reviewed8/46 cited
BHuman-MechanisticDraft12/40 cited
TB-500
Thymosin β4 fragment · Healing
SQ or IM · Multiple sites · 2–3×/week
Thymalin
Immune restorer · Russian peptide bioregulator
IM · Daily for 5–10 days · 1-2×/year
01Mechanism of Action
Parameter
TB-500
Thymalin
Primary target
G-actin (sequestering) + cell-surface integrinsGoldstein 2012
T-cell precursors + thymus-axis maturation pathwayKhavinson 2002
Pathway
Actin remodelling → cell migration; integrin-linked signaling → angiogenesis; anti-inflammatory cytokine modulationGoldstein 2012Malinda 1999
Modulation of T-cell differentiation + thymic hormone restoration in age-involuted thymusKhavinson 2002
Downstream effect
Accelerated wound healing, endothelial migration, hair follicle regeneration, cardiac repair (preclinical)Goldstein 2012
Restored T-cell populations, improved immune surveillance, reduced infection rates in elderlyKhavinson 2002
Feedback intact?
Endogenous protein at baseline; supplementation amplifies
—
Origin
17-AA active fragment of endogenous 43-AA thymosin β4 (TMSB4X gene)Goldstein 2012
Polypeptide fraction isolated from calf thymus extractKhavinson 2002
Antibody development
—
—
02Dosage Protocols
Parameter
TB-500
Thymalin
Standard dose
2 mg per injectionGoldstein 2012
Anecdotal community range; clinical Phase 2 trials used 70–840 mcg/kg IV.
5–10 mg / day IM × 5–10 daysKhavinson 2002
Frequency
2× per week (loading); then 1× per week (maintenance)
Once daily during cycle
Lower / starter dose
1 mg per injection
2.5 mg / day
Evidence basis
Animal-strong + Phase 2 dermal/ocular trialsGoldstein 2012
Russian clinical + in vitroKhavinson 2002
Duration
4–8 weeks loading; longer maintenance for chronic injury
5–10 day cycles, 1–2× per year
Reconstitution
Bacteriostatic water, 1–2 mL per 5 mg vial
Saline or bacteriostatic water
Timing
Evening or pre-rest preferred (anecdotal)
Morning preferred
Half-life
~2 hours (estimated; tissue uptake longer)
Hours (estimated)
04Side Effects & Safety
Parameter
TB-500
Thymalin
Injection site reaction
Mild erythema, transient pain
Mild erythema at IM site
GI symptoms
Rare nausea (anecdotal)
—
Cancer risk
Theoretical via angiogenesis pathway
—
Lethargy / fatigue
Reported anecdotally during loading phase
—
Antibody formation
No data (no long-term human trials)
—
Pregnancy / OB
Avoid
Avoid
Long-term safety
Unknown beyond Phase 2
Limited Western data
Allergic reaction
—
Rare hypersensitivity to bovine-derived polypeptide
Autoimmune flare
—
Theoretical risk in active autoimmune disease
Absolute Contraindications
TB-500
- ·Active malignancy (theoretical angiogenesis concern)
- ·Pregnancy / breastfeeding
Thymalin
- ·Pregnancy / breastfeeding
- ·Bovine protein hypersensitivity
Relative Contraindications
TB-500
- ·Cancer history
- ·Concurrent VEGF inhibitor therapy
Thymalin
- ·Active autoimmune disease
- ·Concurrent immunosuppressant therapy
05Administration Protocol
Parameter
TB-500
Thymalin
1. Reconstitution
Add 1–2 mL bacteriostatic water to 5 mg vial → 2.5–5 mg/mL. Roll gently.
Add 1–2 mL saline or bacteriostatic water per 10 mg vial.
2. Injection site
SQ near injury site (preferred), or systemic SQ (abdomen). Rotate sites.
Intramuscular — deltoid or gluteal. Rotate sites.
3. Timing
Evening or pre-sleep is most common anecdotal timing.
Morning preferred during cycle.
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate, ≤30 days.
Lyophilised: refrigerate, light-protected. Reconstituted: use immediately.
5. Needle
27–31G, 4–8 mm insulin syringe.
23–25G, 25–38 mm IM needle.
06Stack Synergy
TB-500
+ BPC-157
StrongTB-500 and BPC-157 cover complementary halves of tissue repair: BPC-157 upregulates VEGFR2-driven angiogenesis and fibroblast outgrowth; TB-500 sequesters G-actin to enable endothelial / epithelial migration. The anecdotal canonical "healing stack" — pairs especially well for tendon and ligament injuries.
- TB-500
- 2 mg SQ · 2× per week
- BPC-157
- 250–500 mcg SQ · daily
- Primary benefit
- Combined angiogenesis + cell migration for tendon/ligament/muscle repair
Thymalin
+ Thymosin α-1
ModerateThymalin is a polypeptide complex; Thymosin α-1 is a single purified peptide. Both target the thymus-axis but at different levels — Thymalin restores broad thymic signaling; Tα-1 provides a specific molecular activator. Anecdotally combined for elderly immune support.
- Thymalin
- 5–10 mg IM · daily × 7 days
- Thymosin α-1
- 1.6 mg SQ · 2× weekly during the cycle
- Primary benefit
- Broad thymic restoration + targeted immune activation